Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFor most people, yes: semaglutide side effects do go away, or at least ease considerably, within the first few weeks. The gut-related symptoms that start on day one tend to be at their sharpest when treatment begins or after a dose step up, then settle as your body adjusts. That said, the timeline varies, and a small number of people find some symptoms persist longer. Understanding what is typical, what to watch for, and what genuinely warrants medical attention makes the difference between managing treatment well and stopping it prematurely. These are prescription-only medicines; a qualified prescriber reviews your suitability and talks through what to expect as part of any consultation. The NHS patient information on semaglutide gives a useful baseline, and the detail below draws on that alongside the medicine's licensed prescribing information.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide slows the rate at which the stomach empties and acts on receptors involved in appetite and digestion. Both of those effects are useful for weight management, but they also explain why the gut protests, at least initially. If you want a detailed breakdown of what to expect from the very beginning, our guide to semaglutide day 1 side effects covers what commonly shows up in those first hours and days. Nausea is the most commonly reported early symptom; diarrhoea, constipation, indigestion and burping appear too. Headaches and mild fatigue get a mention in the licensed prescribing information as well.
The reason symptoms tend to spike at the beginning and then again after each increase is straightforward: your digestive system is adjusting to a new level of activity at the receptor. STEP 1, the pivotal trial published in the New England Journal of Medicine, found that GI events were most frequent during the dose-escalation phase and fell off over time for most participants. That phased titration schedule (starting low and increasing gradually) exists precisely to give your body time to adapt before the dose climbs.
One thing worth being honest about: even after the initial adjustment, some people notice nausea returning with each step up. That is also normal. It usually passes within days to about two weeks at the new dose. If you are finding a particular level genuinely intolerable, that is a clinical conversation to have with your prescriber rather than a reason to stop quietly. Dose adjustments and titration pacing exist as tools; they are not a sign that treatment has failed.
Most GI symptoms ease. A smaller group of people do report ongoing nausea at maintenance dose, though typically at a lower intensity than at the start. Constipation can be a slow-burn issue rather than a sharp early one, and it sometimes needs active management: adequate fluid, fibre and, where appropriate, guidance from your pharmacist or prescriber.
There is a shorter list of symptoms that should not be waited out. Severe stomach pain (particularly pain that is persistent and radiates toward the back, with or without vomiting) needs urgent medical assessment. In January 2026 the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as a known, infrequent but potentially serious risk with GLP-1 medicines including semaglutide. The update advises stopping treatment and seeking medical help if this symptom pattern develops.
Other situations that warrant prompt contact with a healthcare professional: signs of a gallbladder problem (upper right abdominal pain, fever, jaundice), symptoms of significant dehydration from repeated vomiting or diarrhoea, and any signs of an allergic reaction such as swelling, rash or breathing difficulty. These are uncommon, but they are not something to monitor from home and hope for the best. If anything about your symptoms is making you uncertain, calling 111 or contacting your prescribing service is the right first step, not a forum thread.
It tends to narrow. By the time most people reach a stable maintenance dose, the sharp GI turbulence of the early weeks has usually resolved into something much more manageable, or has gone entirely. Our page on whether the side effects of Wegovy go away looks at this question in detail, including what the clinical data says about how long different symptoms typically last. The broader semaglutide side-effect profile covers the full range in more detail, but the pattern the clinical data consistently shows is: most frequent and most intense early, declining over time for the majority of people who continue.
That picture does not mean everyone finds treatment easy. A minority stop because side effects remain unacceptable even at lower doses. Others find that taking their injection before bed rather than in the morning, staying well hydrated, eating smaller portions, and avoiding high-fat or very rich foods reduces nausea noticeably. These are practical strategies, not medical advice specific to your situation, your prescriber can give guidance tailored to what you are actually experiencing.
Semaglutide is licensed for weight management as Wegovy, and the Wegovy treatment overview sets out the full prescribing context, including the licensed dosing pathway. If you are considering treatment, understanding the side-effect trajectory honestly is part of making an informed decision, and it is a conversation our prescribers have as part of every consultation.
Yes, it matters, practically and collectively. The MHRA's Yellow Card scheme is the UK's system for reporting suspected side effects from any medicine. You do not need to be certain that the medicine caused the problem; a suspicion is enough to report. Patient reports genuinely contribute to post-market surveillance, which is how regulators spot patterns that were not visible in trials.
Reporting is straightforward: the Yellow Card website walks you through it, and it takes under ten minutes. You can report on your own behalf, or a prescriber or pharmacist can do it for you. If you want a fuller picture of what people commonly experience while on the medicine, our guide to side effects from semaglutide brings together the most frequently reported reactions along with practical context for each. If you are on treatment through nume and something concerns you, our aftercare team is available seven days a week, contact details are on the contact page. For broader questions about what to expect from treatment, our FAQs cover many of the questions prescribers hear most often.
The side-effect question is one of the most honest, practical things to think through before starting treatment. If you would like to talk through your individual risk factors and what to expect at each stage, including information on any particular side effect of semaglutide that is on your mind, speak to our prescribers, that conversation is part of every free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.